
Keywords: Overactive bladder; Comparative effectiveness research; Patient-reported outcomes; Registry; Mirabegron; Antimuscarinic; AUA; American Urological Association; ENCePP; European Network of Centres for Pharmacoepidemiology and Pharmacovigilance; EQ-5Dâ¢; Eu